Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03541902 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05465941 | PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | active not recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05501054 | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | active not recruiting | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder(ADAPT-BLADDER) | active not recruiting | Phase 1 / Phase 2 | 186 | Noah Hahn, M.D.OTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04267887 | Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 7 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT04407247 | Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05169970 | A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer | active not recruiting | Phase 2 | 222 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT05842057 | Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy(HAMMER) | active not recruiting | Phase 2 | 118 | University of MiamiOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | active not recruiting | Phase 1 / Phase 2 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT04748042 | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | active not recruiting | Phase 2 | 21 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05024734 | Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids(GAIN-INST) | active not recruiting | Phase 2 | 31 | Roland Seiler-BlarerOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05644041 | Intravesical Gem/Doce in Patients With NMIBC | active not recruiting | Phase 2 | 31 | University of ArizonaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).(INTerpath-004) | active not recruiting | Phase 2 | 272 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Jul 13, 2026 | clinicaltrials |
| NCT05498272 | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations(NePtune) | active not recruiting | Phase 2 | 32 | Rana McKay, MDOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06004661 | Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function | active not recruiting | Phase 2 | 23 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 10, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06029998 | Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion(BORXPTEN) | active not recruiting | Phase 2 | 22 | University of UtahOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03391479 | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 25 | University Health Network, TorontoOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04619069 | Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02489006 | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer(NEO) | active not recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 4 | Jun 23, 2026 | clinicaltrials |
| NCT03016338 | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 51 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04536805 | Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin(REPAIR) | active not recruiting | Phase 1 / Phase 2 | 44 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03476681 | Study of NEO-201 in Solid Tumors Expansion Cohorts | active not recruiting | Phase 1 / Phase 2 | 121 | Precision Biologics, IncINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04419402 | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer(ENZA-p) | active not recruiting | Phase 2 | 162 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03768570 | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | active not recruiting | Phase 2 | 82 | Canadian Cancer Trials GroupNETWORK | 3 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03833479 | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation(ATOMICC) | active not recruiting | Phase 2 | 134 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT01950351 | Hypofractionated Proton Beam Therapy for Localized Prostate Cancer | active not recruiting | Phase 2 | 241 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 28 | TakedaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT00329043 | Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy | active not recruiting | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT00715442 | Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT00756639 | Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium | active not recruiting | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06494150 | Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) | active not recruiting | Phase 2 | 37 | University of OklahomaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02726997 | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | active not recruiting | Phase 1 / Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03375307 | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04251416 | A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | active not recruiting | Phase 2 | 50 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03348670 | Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02717156 | Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | active not recruiting | Phase 2 | 70 | University of Southern CaliforniaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03899987 | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | active not recruiting | Phase 2 | 12 | Roswell Park Cancer InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04190446 | A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer | active not recruiting | Phase 2 | 84 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 16, 2026source: clinicaltrials